These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26408374)

  • 1. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol.
    Archer DF; Thomas MA; Conard J; Merkatz RB; Creasy GW; Roberts K; Plagianos M; Blithe D; Sitruk-Ware R
    Contraception; 2016 Jan; 93(1):58-64. PubMed ID: 26408374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.
    Simmons KB; Kumar N; Plagianos M; Roberts K; Hoskin E; Han L; Alami M; Creasy G; Variano B; Merkatz R
    Contraception; 2018 Mar; 97(3):270-276. PubMed ID: 29097225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
    Rad M; Kluft C; Ménard J; Burggraaf J; de Kam ML; Meijer P; Sivin I; Sitruk-Ware RL
    Am J Obstet Gynecol; 2006 Jul; 195(1):72-7. PubMed ID: 16545330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with nonadherence to instructions for using the Nestorone®/ethinyl estradiol contraceptive vaginal ring.
    Stifani BM; Plagianos M; Vieira CS; Merkatz RB
    Contraception; 2018 May; 97(5):415-421. PubMed ID: 29269252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE.
    Rad M; Burggraaf J; de Kam ML; Cohen AF; Kluft C
    Contraception; 2012 Sep; 86(3):231-7. PubMed ID: 22445437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
    Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
    Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein.
    Rad M; Burggraaf J; Sitruk-Ware RL; de Kam ML; Cohen AF; Kluft C
    Steroids; 2012 Nov; 77(13):1483-6. PubMed ID: 22982353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction.
    Merkatz RB; Plagianos M; Hoskin E; Cooney M; Hewett PC; Mensch BS
    Contraception; 2014 Nov; 90(5):514-21. PubMed ID: 24993487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.
    Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Sivin I; Tsong YY; Fraser IS
    Contraception; 2005 Jul; 72(1):46-52. PubMed ID: 15964292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.
    Jensen JT; Edelman AB; Chen BA; Archer DF; Barnhart KT; Thomas MA; Burke AE; Westhoff CL; Wan LS; Sitruk-Ware R; Kumar N; Variano B; Blithe DL
    Contraception; 2018 May; 97(5):422-427. PubMed ID: 29409834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.
    Croxatto HB; Brache V; Massai R; Alvarez F; Forcelledo ML; Pavez M; Cochon L; Salvatierra AM; Faundes A
    Contraception; 2006 Jan; 73(1):46-52. PubMed ID: 16371294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined hormonal vaginal ring in comparison to combined hormonal pills in heavy menstrual bleeding.
    Dahiya P; Dalal M; Yadav A; Dahiya K; Jain S; Silan V
    Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():147-51. PubMed ID: 27285306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
    Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
    J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women.
    Brache V; Merkatz R; Kumar N; Jesam C; Sussman H; Hoskin E; Roberts K; Alami M; Taylor D; Jorge A; Croxatto H; Lorange E; Mishell DR; Sitruk-Ware R
    Contraception; 2015 Oct; 92(4):289-97. PubMed ID: 26032952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol.
    Tiedeken M; Westhoff CL; Cohen A; Cremers S; Sitruk-Ware R; Blithe DL;
    Contraception; 2019 Jun; 99(6):329-334. PubMed ID: 30871934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.